Novoprotein(SH:688137)2023-04-28 16:00Financial Performance - The company reported a significant increase in revenue, achieving a total of $X million for the fiscal year, representing a Y% growth compared to the previous year[16]. - The company's operating revenue for 2022 was ¥264,553,718, a decrease of 22.62% compared to ¥341,895,855.16 in 2021[28]. - The net profit attributable to shareholders decreased by 39.32% to ¥90,416,734.36 from ¥149,005,616.48 in the previous year[30]. - The net profit after deducting non-recurring gains and losses fell by 47.88% to ¥77,596,888.20 compared to ¥148,869,293.75 in 2021[30]. - The company achieved operating revenue of RMB 87,842,857.29, a year-on-year increase of 12% compared to RMB 78,494,682.3 in 2021[33]. - The net profit attributable to shareholders was RMB 39,897,088.36, representing a 27% increase from RMB 31,405,202.5 in the previous year[33]. - The company reported cash flow from operating activities of RMB 7,020,963.80, an increase from RMB 4,114,032.74 in 2021[33]. - The company reported a significant increase in cash and cash equivalents, with a net increase of 739,935,737.21 RMB, up 512.77% from the previous year[162]. - The company achieved operating revenue of ¥264,553,718, a decrease of 22.91% compared to the previous year, with product revenue at ¥255,579,959.75[144]. - The company reported a significant increase in revenue, achieving a total of $1.5 billion for the fiscal year, representing a 20% year-over-year growth[194]. - The company reported a significant increase in revenue, achieving a total of $500 million for the fiscal year, representing a 20% year-over-year growth[196]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion in 2022, representing a 20% growth compared to the previous year[199]. Market Presence and Client Engagement - As of the end of the reporting period, the company has over 100 clients in the mRNA vaccine production sector, indicating a growing market presence[4]. - The company is expanding its market presence, targeting D new regions, which is expected to enhance overall market share by E%[16]. - The company is actively pursuing market expansion through the development of new diagnostic reagents and mRNA vaccine candidates[118]. - The company plans to increase marketing personnel and enhance customer engagement to expand its business in emerging markets[148]. - The company is focusing on sustainability initiatives, aiming to reduce carbon emissions by 25% over the next five years[194]. - The company is exploring potential acquisitions to strengthen its market position, with a budget of 300 million allocated for this purpose[199]. Research and Development - The R&D budget has increased by G%, focusing on advancements in gene editing and mRNA vaccine technologies[16]. - The company launched over 100 new innovative products during the reporting period, enhancing its product offerings[44]. - The company added 34 new R&D personnel, increasing its investment in research and development[44]. - The company reported a total R&D investment of approximately ¥41.1 million, representing a 20.55% increase compared to the previous year, with R&D expenses accounting for 15.54% of total revenue[115]. - The company is developing a one-stop service for innovative antibody research and mRNA synthesis, successfully serving dozens of clients[112]. - The company is actively collaborating with research institutions and universities to advance the development of mRNA vaccines in basic research[61]. - The company has developed 23 core technologies related to protein design, modification, and production, which remain unchanged during the reporting period[97]. - The company has established a comprehensive technology platform for antibody discovery and diagnostic reagents, leveraging expertise in molecular biology and protein engineering[97]. - The company is focusing on mRNA technology, aiming to provide related CRO services and expand into emerging fields like organoids and cell therapy[178]. Competitive Landscape and Risks - The company faces risks of revenue decline in its mRNA raw enzyme and diagnostic antibody businesses due to industry competition and uncertainties in client product development[4]. - The recombinant protein and related technology service market is expanding rapidly, attracting more domestic and international competitors, which may increase competitive pressure on the company[5]. - There is a risk of increased inventory levels due to market changes, which could lead to unsold products and potential write-downs[6]. - The company acknowledges the potential for intensified market competition and the need for increased R&D investment to maintain its competitive edge[5]. - The company faces risks related to the fluctuation of product sales prices, which have shown a downward trend[139]. Strategic Initiatives - The company plans to distribute a cash dividend of RMB 5.00 per 10 shares, totaling RMB 35,087,719.50, which represents 38.8% of the net profit attributable to shareholders for 2022[8]. - The company does not plan to issue bonus shares or convert capital reserves into share capital for the 2022 fiscal year[8]. - The company will enhance its marketing and service capabilities to improve customer coverage and satisfaction[178]. - The company aims to increase market share by expanding its business team and enhancing digital marketing efforts[181]. - The company will consider investments and acquisitions in related upstream and downstream industries to enhance its business and industry layout[184]. Operational Efficiency - The gross margin improved to I%, reflecting better cost management and operational efficiencies[16]. - The company has implemented a comprehensive quality management system that includes periodic audits of raw material suppliers and stringent testing for residual impurities[128]. - The company has successfully implemented a quality management system compliant with GMP standards, ensuring product safety and stability through rigorous quality control measures[126]. - The company achieved significant advancements in mRNA vaccine drug development, including the launch of GMP-grade nucleotides and modified nucleotides, contributing to clinical projects and regulatory approvals for multiple partners[109]. Shareholder Engagement - The company held its first extraordinary general meeting of 2022 on March 4, 2022, where all proposals were approved by shareholders[187]. - The second extraordinary general meeting took place on November 28, 2022, with all proposals also receiving shareholder approval[188]. - The total pre-tax remuneration for key management personnel during the reporting period amounted to CNY 577.42 million[191]. - The chairman and general manager, Zhu Huaxing, maintained a shareholding of 15,343,004 shares throughout the year[190]. - The company’s board of directors and senior management have remained stable with no significant changes in shareholdings[190].